LUIS ALBERTO RUIZ ITURRIAGA-rekin lankidetzan egindako argitalpenak (21)

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2023

  1. High-flow nasal cannula oxygen therapy for the treatment of acute respiratory failure secondary to SARS-CoV-2 pneumonia out of ICU

    Clinical Respiratory Journal, Vol. 17, Núm. 9, pp. 905-914

  2. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Science of the Total Environment, Vol. 894

  3. Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia

    Infection, Vol. 51, Núm. 5, pp. 1319-1327

  4. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

    Frontiers in Medicine, Vol. 10

  5. Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing

    International Journal of Infectious Diseases, Vol. 134, pp. 106-113

  6. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  7. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 59, Núm. 1, pp. 19-26

2022

  1. Author Correction: Machine learning-based model for prediction of clinical deterioration in hospitalized patients by COVID 19 (Scientific Reports, (2022), 12, 1, (7097), 10.1038/s41598-022-09771-z)

    Scientific Reports

  2. Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities

    International Journal of Infectious Diseases, Vol. 115, pp. 39-47

  3. Bacteremic pneumococcal pneumonia: arrhythmogenic disease

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

  4. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences

    Infection, Vol. 50, Núm. 1, pp. 179-189

  5. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781

  6. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia

    Journal of Infection, Vol. 85, Núm. 6, pp. 644-651

2021

  1. New-onset atrial fibrillation in patients with pneumococcal pneumonia. Impact of timing and duration on short- and medium-term mortality

    Journal of Infection, Vol. 82, Núm. 1, pp. 67-75

  2. Predictors of mortality of COVID-19 in the general population and nursing homes

    Internal and Emergency Medicine, Vol. 16, Núm. 6, pp. 1487-1496

  3. Pulmonary Function in Early Follow-up of patients with COVID-19 Pneumonia

    Archivos de Bronconeumologia, Vol. 57, pp. 75-76

  4. RDW-based clinical score to predict long-term survival in community-acquired pneumonia: a European derivation and validation study

    Internal and Emergency Medicine, Vol. 16, Núm. 6, pp. 1547-1557

2020

  1. Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome

    Infectious Diseases, Vol. 52, Núm. 9, pp. 603-611

2019

  1. Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001–2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain)

    Vaccine, Vol. 37, Núm. 29, pp. 3840-3848